NNT to prevent one LRTI or one death and absolute risk reduction by antiviral therapy at URTI stage to prevent progression to LRTI and RSV-associated mortality
| . | Progression to LRTI . | RSV-associated mortality . | ||
|---|---|---|---|---|
| Outcome . | NNT . | Absolute risk reduction, % (95% CI) . | NNT . | Absolute risk reduction, % (95% CI) . |
| Without application of ISI-RSV | ||||
| Total cohort (n = 237) | 6 | 20 (9-31) | 15 | 7 (0-13) |
| After application of ISI-RSV | ||||
| Low-risk group | 8 | 14 (0-29) | NA | 0 |
| Moderate-risk group | 9 | 12 (0-26) | 45 | 2 (0-9) |
| High-risk group | 2 | 85 (65-104) | 2 | 55 (18-91) |
| . | Progression to LRTI . | RSV-associated mortality . | ||
|---|---|---|---|---|
| Outcome . | NNT . | Absolute risk reduction, % (95% CI) . | NNT . | Absolute risk reduction, % (95% CI) . |
| Without application of ISI-RSV | ||||
| Total cohort (n = 237) | 6 | 20 (9-31) | 15 | 7 (0-13) |
| After application of ISI-RSV | ||||
| Low-risk group | 8 | 14 (0-29) | NA | 0 |
| Moderate-risk group | 9 | 12 (0-26) | 45 | 2 (0-9) |
| High-risk group | 2 | 85 (65-104) | 2 | 55 (18-91) |
NA, not applicable due to 0 deaths in low-risk group.